Preclinical evaluation of abuse potential of the peripherally-restricted kappa opioid receptor agonist HSK21542
- 23 October 2024
- journal article
- research article
- Published by Elsevier in Regulatory Toxicology and Pharmacology
- Vol. 154, 105731
Abstract
No abstract availableKeywords
This publication has 36 references indexed in Scilit:
- Pharmacokinetics, Mass Balance and Metabolism of [14C]HSK21542, a Novel Kappa Opioid Receptor Agonist, in HumansEuropean Journal of Drug Metabolism and Pharmacokinetics, 2023
- VU0155041, a positive allosteric modulator of mGluR4, in the nucleus accumbens facilitates extinction and inhibits the reinstatement of morphine-induced conditioned place preference in male ratsBrain Research Bulletin, 2023
- Structures of the entire human opioid receptor familyCell, 2023
- Preclinical Studies on Nalfurafine (TRK-820), a Clinically Used KOR Agonist2021
- Modulation of cocaine-related behaviors by low doses of the potent KOR agonist nalfurafine in male C57BL6 micePsychopharmacology, 2020
- Nucleus accumbens hyperpolarization-activated cyclic nucleotide-gated channels modulate methamphetamine self-administration in ratsPsychopharmacology, 2016
- Nalfurafine hydrochloride, a selective κ opioid receptor agonist, has no reinforcing effect on intravenous self-administration in rhesus monkeysJournal of Pharmacological Sciences, 2016
- Effects of TRK-820, a selective kappa opioid receptor agonist, on rat schizophrenia modelsEuropean Journal of Pharmacology, 2009
- Mu opioid receptor: a gateway to drug addictionCurrent Opinion in Neurobiology, 2004
- Effects of a newly synthesized κ-opioid receptor agonist, TRK-820, on the discriminative stimulus and rewarding effects of cocaine in ratsPsychopharmacology, 2002